DNA
Zephyr Labz will be working with a DNA testing company to provide products to address solutions based on genetic test indications. The DNA test maps each userʼs endocannabinoid system and matches the results with a specific cannabinoid ratio and terpene profile aligned with their genotype. Our team of research scientists developed a protocol to align distinctive markers found in the genetic test results with products to help consumers treat or offset a variety of health conditions. Genetic tests like these are being used in diagnosing mental conditions, including depression, anxiety, OCD, and even more. Based on these test results, we can recommend the most effective wellness products for any specific condition.
Gene Editing
Gene editing technology called CRISPR was first demonstrated in 2012-2013 by UC-Berkley and MIT/Harvard. Genome editing represents a new era in medicine. Our team of experts is combining the power of CRISPR with the therapeutic potential of cannabinoids and the discovery of novel anti-cancer pathways to develop a suite of innovative drugs aimed at treating some of the most pressing medical conditions of our time. In addition to CRISPR, Zephyr Labz is implementing other gene editing technologies as we are aggressive in our drug development strategies.
We believe that our unique approach to drug development, which incorporates the development of new molecular entities as well as novel drug delivery technologies, will allow us to create truly transformative treatments with the potential to improve the lives of millions of people. Whether it be fighting cancer, slowing the effects of aging, or treating debilitating mental illness, Zephyr Labz is at the forefront of medical innovation.
